Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793294 | 0.87 | CYP3A4 (0.54) | CYP3A4TSHRPIK3CAALDH1A1HSD17B10 | |
| SCHEMBL29788122 | 0.84 | ALDH1A1 (0.62) | CYP3A4TSHRPIK3CAALDH1A1HSD17B10 | |
| SCHEMBL365320 | 0.84 | ALDH1A1 (0.62) | CYP3A4TSHRPIK3CAALDH1A1HSD17B10 | |
| SCHEMBL27553519 | 0.83 | CYP3A4 (0.50) | CYP3A4TSHRPIK3CAALDH1A1HSD17B10 | |
| SCHEMBL29414657 | 0.83 | CD44 (0.48) | CYP3A4TSHRPIK3CAALDH1A1ADORA2A | |
| SCHEMBL2602432 | 0.83 | CD44 (0.48) | CYP3A4TSHRPIK3CAALDH1A1ADORA2A | |
| SCHEMBL394565 | 0.82 | ALDH1A1 (0.65) | CYP3A4TSHRPIK3CAALDH1A1ADORA2A | |
| SCHEMBL30839749 | 0.81 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CAALDH1A1ADORA2A | |
| SCHEMBL2206282 | 0.81 | CYP3A4 (0.72) | CYP3A4TSHRPIK3CAALDH1A1ADORA2A | |
| SCHEMBL23625587 | 0.81 | ALDH1A1 (0.54) | CYP3A4TSHRPIK3CAALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199239-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199239-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199239-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060074111-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2006-04-06 | — | — | US | disclosed |
| EP-1513795-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000762-A2 | PROPIONIC ACID DERIVATIVES AND THEIR USE AS HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074111-A1 | Chemical compounds | HDAC3, HAT1, H1-3 | CYP3A4 136/4885TSHR 849/4885PIK3CA 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.